Kura Oncology is a clinical stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura s pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. The company s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor. The company s preclinical pipeline includes KO , an ERK inhibitor, and a menin MLL inhibitor program.
Quote | Kura Oncology Inc. (NASDAQ:KURA)
Last: | $18.635 |
---|---|
Change Percent: | -0.61% |
Open: | $18.26 |
Close: | $18.75 |
High: | $18.8 |
Low: | $17.96 |
Volume: | 220,407 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Kura Oncology Inc. (NASDAQ:KURA)
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2024 financial results after the cl...
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – SAN DIEGO, April 22, 2024 (GLOB...
Message Board Posts | Kura Oncology Inc. (NASDAQ:KURA)
Subject | By | Source | When |
---|---|---|---|
* * $KURA Video Chart 04-28-2020 * * | ClayTrader | investorshub | 04/28/2020 9:04:32 PM |
Anybody out there? ! | seppi08162 | investorshub | 12/19/2019 5:52:35 PM |
KURA buy 19.00 | stocktrademan | investorshub | 02/11/2018 5:50:43 PM |
Feels risky here...feels like they're purposely notching it | Lone Wolf | investorshub | 09/08/2017 3:17:02 PM |
Looks like the markets are really starting to | Lone Wolf | investorshub | 09/08/2017 2:26:26 PM |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizi...
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2024 financial results after the cl...
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – SAN DIEGO, April 22, 2024 (GLOB...